Dcytb (Cybrd1) functions as both a ferric and a cupric reductase in vitro  by Wyman, Steven et al.
FEBS Letters 582 (2008) 1901–1906Dcytb (Cybrd1) functions as both a ferric and a cupric reductase in vitro
Steven Wyman, Robert J. Simpson, Andrew T. McKie, Paul A. Sharp*
Kings College London, Iron Metabolism Group, Nutritional Sciences Division, Franklin-Wilkins Building, 150 Stamford Street,
London SE1 9NH, United Kingdom
Received 2 April 2008; revised 18 April 2008; accepted 7 May 2008
Available online 20 May 2008
Edited by Miguel De la RosaAbstract MDCK cells expressing an inducible duodenal cyto-
chrome b-green ﬂuorescent protein (Dcytb-EGFP) fusion con-
struct were used to investigate the function of Dcytb. The
Dcytb-EGFP protein was targeted correctly to the plasma mem-
brane, and cells displayed increased ferric and cupric reductase
activities, which were greatly reduced in the presence of doxycy-
cline. The data suggests that Dcytb plays a physiological role in
both iron and copper uptake, through divalent metal transporter
1 (DMT1) and copper transporter 1, respectively. In support of
this hypothesis, we show that 59Fe uptake was signiﬁcantly en-
hanced in Dcytb-EGFP expressing MDCK cells which endoge-
nously express DMT1.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Iron and copper are essential for life in most living organ-
isms being required for a wide variety of cellular processes,
ranging from DNA and neurotransmitter synthesis to haem
biosynthesis and as prosthetic groups within key enzymes re-
quired for oxidative phosphorylation and the TCA cycle.
The processes of dietary import for iron and copper in mam-
mals share some similarities. For example, both metals are ab-
sorbed in the duodenum via speciﬁc carriers which require the
metal to be in the reduced state i.e. ferrous Fe(II) and cuprous
Cu(I), prior to being taken up via their respective transporters
divalent metal transporter 1 (DMT1) [1,2] and copper trans-
porter 1 (Ctr1) [3–6].
A variety of ferric reductases have been shown to aid the
acquisition of iron, for example the FRE family of metallore-
ductases in yeast [7,8] and the FRO protein in plants [9]. In
yeast, both Fre1 and Fre2 have been shown to reduce copper
as well as iron and to increase copper uptake [10,11]. In mam-
mals two major ferric reductase families have been described,
duodenal cytochrome b (Dcytb) [12] and related cytochromesAbbreviations: Ctr1, copper transporter 1; Dcytb, duodenal cyto-
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doi:10.1016/j.febslet.2008.05.010b561 homologues [13–15] and more recently the Steap family
of metalloreductases [16,17]. Interestingly in addition to their
ferrireductase activity, a number of the Steap proteins can also
reduce copper [17].
Dcytb was identiﬁed using a subtractive cloning strategy
which also identiﬁed other important iron transport proteins
including ferroportin [12,18]. Dcytb is a 286 amino acid, six
transmembrane domain, plasma membrane protein that exhib-
its reductase activity in both nitro-blue tetrazolium and ferric
nitrilotriacetic acid assays [12]. In addition, Dcytb mRNA
and protein are rapidly induced in response to iron deﬁciency
and hypoxia indicating that it may play a pivotal role in iron
metabolism [12]. Expression studies revealed Dcytb to be local-
ised predominantly to the duodenal brush border membrane
and it was therefore suggested that it was involved with uptake
of dietary inorganic iron, acting in concert with DMT1 [12].
However, the role of Dcytb in iron metabolism remains un-
clear. There are no reports of impaired iron metabolism being
associated with mutations in human Dcytb. Furthermore, ge-
netic deletion of Dcytb in mice failed to show a pronounced
defect in iron acquisition and utilisation [19]. It has been sug-
gested that this lack of phenotype may be due to the presence
of other reductases in the gut [19], e.g. Steap3 or related family
members. However, mRNA expression of the Steap metallore-
ductases in the intestine is relatively low and none have been
shown to be iron-regulated [16,17]. Furthermore, while the
sub-cellular localisation of the Steap proteins in the gut is
not known, studies of their function and localisation in other
tissues indicate that it is likely to be endosomal [16]. Hence
for these reasons it is unlikely that Steap3 or other family
members would make a major contribution to the ferric reduc-
tase activity of the duodenal mucosa [16].
A further explanation for the lack of phenotype in Dcytb
knockout mice might be the presence of other compensatory
factors in the intestinal lumen such as ascorbate. Ascorbic acid
is a normal constituent of gastric juice and other gastric secre-
tions even in scorbutic species [20]. However, levels of ascorbic
acid secreted into the gut lumen may vary widely between spe-
cies and might be substantially higher in mice, which can gen-
erate ascorbate from glucose. Interestingly, we have shown
that ascorbate levels in the duodenal mucosa are iron-regu-
lated, being increased in iron deﬁcient and hypotransferrinae-
mic mice and by iron deﬁciency in humans [21,22].
To understand the role of Dcytb in metal homeostasis, we
have characterized the functional capabilities of Dcytb
in vitro. We demonstrate that Dcytb has the capacity to reduce
both iron and copper complexes. These eﬀects were markedly
increased when cells were loaded with dehydroascorbate
(DHA), which increases intracellular ascorbate. Furthermore,blished by Elsevier B.V. All rights reserved.
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nously express DMT1, signiﬁcantly increases iron uptake, indi-
cating that Dcytb has a role in cellular iron transport.2. Materials and methods
2.1. Transfection and cell culture
Murine Dcytb cDNA was PCR ampliﬁed from duodenal mRNA
and cloned into the pEGFP-N1 (Clontech, Palo Alto, USA) to gener-
ate a green ﬂuorescent protein (EGFP) C-terminal tagged Dcytb con-
struct. The expression of the Dcytb-EGFP protein was then placed
under the control of an inducible promoter, the tetracycline responsive
element (TRE) of the pTRE2hyg vector (Clontech, Palo Alto, USA).
The tagged sequence was PCR ampliﬁed and cloned into the pTRE2-
hyg vector (Clontech, Palo Alto, USA) generating a ﬁnal pTRE2hyg-
Dcytb-EGFP vector construct. Each construct was fully sequenced
(Lark Technologies, Cogenics, Clinical Data Inc., Newton, USA) to
ensure no mutations were introduced during the cloning process.
Tetracycline-Oﬀ Madin-Darby Canine Kidney (TET-Oﬀ MDCK)
cells (Clontech, Palo Alto, USA) were transfected with the pTRE2-
hyg-Dcytb-EGFP vector using lipofectamine2000 (Invitrogen, Paisley,
UK) as per the manufacturers instructions. Cells were the cultured for
2 weeks in Dulbeccos modiﬁed Eagles medium (Sigma–Aldrich, Gill-
ingham, UK) supplemented with 10% TET system approved fetal bo-
vine serum (Clontech, Palo Alto, USA), penicillin/streptomycin
(Sigma–Aldrich, Gillingham, UK), 1 ng/ml puromycin (Clontech, Palo
Alto, USA) and 200 lg/ml hygromycin (Calbiochem, Merck KGaA,
Darmstadt, Germany).
Expression of Dcytb-EGFP was knocked down by addition of
20 ng/ml doxycycline (Clontech, Palo Alto, USA) to culture medium
for 4 days. Prior to either ferric or cupric reductase assays cells were
treated with either: 100 lM DHA (Sigma–Aldrich, Gillingham, UK)
for 4 h; 100 lg/ml phloretin (Calbiochem, Merck KGaA, Darmstadt,
Germany) for 30 min followed by 100 lM DHA for 4 h; or 100 lM
DHA with 1 U/ml ascorbate oxidase (Sigma–Aldrich, Gillingham,
UK).
2.2. Confocal microscopy
pTRE2hyg-Dcytb-EGFP transfected cells were cultured in Lab-
TEK chambered coverglass slides (Nunc, Thermo Fisher Scientiﬁc,
Loughborough, UK). Confocal microscopy was performed using a
Leica LS2 confocal microscope (Leica Microsystems UK Ltd., Milton
Keynes, UK) and images captured using the 40· objective using an
excitation wavelength of 488 nm to visualise the EGFP-tagged pro-
teins.
2.3. Western blotting
Cell monolayers were homogenised in ice cold sucrose buﬀer
[250 mM sucrose (Sigma–Aldrich, Gillingham, UK), 10 mM Tris (Sig-
ma–Aldrich, Gillingham, UK), pH 7.5], supplemented with protease
inhibitors [1 mM PMSF and 1 lg/ml leupetin and pepstatin] in a Tef-
lon homogeniser prior to centrifugation at 700 · g for 15 min. Protein
containing supernatant was denatured at 100 C for 3 min in an equal
volume of Laemmli sample buﬀer before loading onto a 10% SDS–
PAGE gel. Samples were transferred to a nitrocellulose membrane be-
fore blocking overnight in ice-cold phosphate buﬀered saline (PBS)
containing 5% fat free milk and 0.1% Tween 20. To detect Dcytb-
EGFP, the membrane was probed with a murine anti-GFP (JL-8,) pri-
mary antibody (Clontech, Palo Alto, USA). Endogenous DMT1 pro-
tein was detected using rabbit anti-DMT1 (NRAMP24-A) antibody
(Alpha Diagnostics Inc., San Antonio, Texas, USA). Cross reactivity
was detected with HRP-conjugated secondary antibodies (Dako, Ely,
UK) and visualised using the SuperSignal West Femto detection sys-
tem (Pierce, Rockford, USA).
2.4. Cupric and ferric reductase assays
Dcytb-EGFP transfected and untransfected TET-Oﬀ MDCK cells
were plated into 24 well plates and grown for 1 week post-conﬂuency
before performing reductase assays. The cells were washed three times
in PBS, pH 7.0 before incubation in a physiological buﬀer [25 mM
MOPS, 25 mM MES, 5.4 mM KCl, 5 mM glucose, 140 mM NaCl,
1.8 mM CaCl2, 800 lM MgCl2] supplemented with either 50 lMFe(III)-nitrilotriacetic acid (NTA) and 200 lM 3-(2-pyridyl)-5,6-diphe-
nyl-1,2,4-triazine-4 0,400-disulfonic acid sodium salt (ferrozine) or 50 lM
Cu(II)-NTA and 200 lM bathocuprionedisulfonate (BCS) for the iron
and copper assays, respectively. The reduction of iron was measured
by the formation of the coloured Fe(II)-ferrozine complex and moni-
toring the change in absorbance at 562 nm. Similarly, the formation
of the Cu(I)-BCS complex was monitored by the change in absorbance
at 482 nm. Standard curves were generated to convert the absorbance
value into pmoles of iron or copper reduced. All reactions were per-
formed in the dark at 37 C unless stated.
2.5. Iron uptake assays
Cells were prepared as per the reductase assay. After washing in
PBS, cells were incubated for 10 min in room temperature pH 7.5
Hanks Balanced Salt Solution (HBSS) [5 mM KCl, 4.2 mM KHCO3,
0.36 mM K2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2 Æ 2H2O, 0.5 mM
MgCl2 Æ 6H2O, 140 mM NaCl, 10 mM N-2-hydroxyethylpiperazine-
N 0-2-ethanesulphonic acid]. Cells were then incubated at room temper-
ature in pH 5.5 HBSS containing 10 lM 59Fe(III)-NTA. After incuba-
tion cells were washed three times with ice cold pH 7.5 HBSS and then
lysed in 0.5 M NaOH before gamma counting.
2.6. Data analysis
Data are presented as the mean ± S.E.M. Statistical analysis was
carried out using SPSS statistics package, and utilised one-way ANO-
VA followed by Tukeys post hoc test or Students unpaired t-test
where appropriate. Diﬀerences were considered signiﬁcant at P < 0.05.3. Results and discussion
Dcytb remains one of the most highly (and rapidly) iron-
responsive mRNA or proteins so far described. Here we have
examined the functional capabilities of the Dcytb protein in
iron reduction as well as investigating its potential physiologi-
cal role in reduction of copper using an inducible polarised epi-
thelial cell system.
Dcytb-EGFP protein was expressed on the plasma mem-
brane of transfected cells and expression was knocked down
in the presence of doxycycline (Fig. 1). The expression of
Dcytb-EGFP was associated with a signiﬁcant increase in the
cellular capacity to reduce ferric iron (Fig. 2A) supporting
our previous data [12]. In untransfected cells, ferric reductase
activity was extremely low and could not be detected above
the background of the assay until some 90 min after the addi-
tion of iron. The low endogenous reductase activity in MDCK
cells is one of the features that make them a suitable vehicle for
investigating Dcytb function in vitro. Ferric reductase activity
in Dcytb-EGFP expressing MDCK cells was pH-dependent
(Fig. 2B) reﬂecting the greater solubility of ferric iron at acid
pH. Furthermore, the process displayed Michaelis–Menten
kinetics with increasing concentrations of ferric NTA, and
was susceptible to changes in the experimental temperature
(Fig. 2C and Table 1).
Like iron, copper must also be reduced before it is taken up
across cell membranes [23]. Our data support a role for Dcytb
as a cupric reductase (Fig. 3A). Interestingly, unlike iron, the
reduction of copper (II) did not display a strong pH-depen-
dency but copper reduction was maximal at neutral pH
(Fig. 3B). Cupric reductase activity was saturable with excess
copper and enzyme kinetics varied with experimental tempera-
ture (Fig. 3C and Table 2).
Previous work has shown that known members of the cyto-
chrome b561 family of reductases, including Dcytb, are ascor-
bate dependent enzymes [24], and our data further highlight
intracellular ascorbate levels as an important factor in deter-
Fig. 1. Inducible Dcytb-EGFP expression in MDCK Tet-Oﬀ cells. (A) Confocal images of EGFP signal (green) in transfected MDCK cells in the
presence or absence of 20 ng/ml doxycyline. In the absence of doxycycline prominent plasma membrane localisation of Dcytb-EGFP can be
observed. (B) Western blot of protein extracted from cells treated with 20 ng/ml doxycyline compared with untreated cells. A clear band of
approximately 55 kDa is visible corresponding to the expected size of the Dcytb-EGFP fusion protein.
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Fig. 2. Dcytb functions as a ferric reductase. (A) Time course of reduction of ferric NTA in Dcytb-EGFP over-expressing- (solid line) and non-
transfected (dashed line) MDCK cells. Statistical diﬀerences, *P < 0.01, between transfected and untransfected cells at each time point were
determined using Students unpaired t-test. (B) Eﬀect of extracellular pH on ferric reductase activity. Data bars that do not share common letters
(uppercase – transfected cells; lowercase – untransfected cells) are signiﬁcantly diﬀerent from each other (P < 0.05, one-way ANOVA and Tukeys
post hoc test). (C) Concentration-dependent relationships for the reduction of ferric NTA by Dcytb at 22 C () and 37 C (n). The kinetic
parameters derived from Michaelis–Menten analysis of these data are shown in Table 1. Data are mean ± S.E.M. of four to six observations in each
group.
S. Wyman et al. / FEBS Letters 582 (2008) 1901–1906 1903mining Dcytb activity (Fig. 4). We found that preloading cells
with the oxidised form of ascorbate (DHA) had a profound ef-
fect – greatly increasing both ferric and cupric reductase activ-
ities (Fig. 4A and B). This eﬀect was blocked by inhibiting
DHA uptake using the GLUT transporter inhibitor phloretin.
It is well known that a number of cell types, including entero-
cytes and renal tubular epithelial cells, are able to utilise vari-
ous GLUT transporters to transport DHA [25–27]. DHA israpidly reduced inside cells using glutathione or glutaredoxin
[28] to generate ascorbic acid. Our data indicate that levels
of intracellular ascorbate are an important determinant of
Dcytb activity.
Interestingly, Dcytb has recently been localised to the mem-
branes of mature red blood cells from scorbutic species such as
humans and guinea pigs leading to the conclusion that it may
play a role in ascorbate regeneration in some tissues [14]. In
Table 2
Dcytb-EGFP cupric reductase kinetics
22 C 37 C Statistics
Km (lM) 15.2 ± 1.6 23.1 ± 2.5 NS
Vmax
(pmol/lg cell protein/min)
3.18 ± 1.61 8.34 ± 0.20 P < 0.05
Copper reduction was measured using 50 lM cupric NTA and 200 lM
BCS. Experimental conditions and data analysis were as described in
the legend to Table 1.
Table 1
Dcytb-EGFP ferric reductase kinetics
22 C 37 C Statistics
Km (lM) 92.1 ± 19.4 74.0 ± 5.9 NS
Vmax
(pmol/lg cell protein/min)
2.18 ± 0.13 4.48 ± 0.10 P < 0.05
Cells were prepared as described in Section 2, and incubated with
50 lM ferric NTA and 200 lM ferrozine for 10 min at either 22 C or
37 C. Reductase data was analysed using GraphPad Prism (Graph-
Pad Software Inc., San Diego, CA, USA) to generate kinetic param-
eters.
1904 S. Wyman et al. / FEBS Letters 582 (2008) 1901–1906vitro we found that the presence of ascorbate oxidase, which
abolishes all extracellular ascorbate, had no eﬀect on the abil-
ity of Dcytb to reduce either iron or copper (Fig. 4A and B)
indicating that reductase activity was not secondary to either
extracellular ascorbate regeneration by Dcytb or ascorbate
secretion from the cell monolayer into the incubation medium.
The reduction of both iron and copper in MDCK cells was
speciﬁcally dependent on Dcytb-EGFP expression and could
be inhibited by incubation with doxycycline (Fig. 4A and B).
In addition to metal–NTA complexes, more physiological
forms of both iron (ferric citrate) and copper (cupric-histidine)
were also eﬀectively reduced by Dcytb (Fig. 5A and B). Since
MDCK cells endogenously express DMT1 [29,30], we utilised0
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Fig. 3. Dcytb functions as a cupric reductase. (A) Time course of reduction
transfected (dashed line) MDCK cells. Statistical diﬀerences, *P < 0.01, b
determined using Students unpaired t-test. (B) Eﬀect of extracellular pH on
(uppercase – transfected cells; lowercase – untransfected cells) are signiﬁcant
post hoc test). (C) Concentration-dependent relationships for the reductio
parameters derived from Michaelis–Menten analysis of these data are shown
group.this function to determine whether Dcytb might work in con-
cert with DMT1, reducing ferric iron and presenting it in the
absorbable ferrous form. Over-expression of Dcytb-EGFP in
MDCK cells led to a signiﬁcant increase in 59Fe uptake
(Fig. 6). In contrast to previous studies with Dcytb knockout
mice [19], these data provide evidence that Dcytb plays a role
in cellular iron acquisition. It remains to be determined
whether Dcytb plays a direct role in copper absorption. While
DMT1 is ﬁrmly established as the major transporter for inor-
ganic iron, the nature of the epithelial copper transporter is less
clear. Both DMT1 and Ctr1 have been shown to transport
copper in vitro in intestinal Caco-2 cells and renal MDCK cells
[31–33]. However, a recent study demonstrated that Ctr1 was
localised to the basolateral and not the apical membrane in
these cell types [33]. Furthermore, apical copper uptake in both0
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S. Wyman et al. / FEBS Letters 582 (2008) 1901–1906 1905Caco-2 cells and MDCK cells appeared to occur via a non-
DMT1 mechanism [33].
In conclusion, we have shown that Dcytb can function as
both a ferric and a cupric reductase in vitro. While the Steap
proteins are known to possess both ferric and cupric reductase
activity [17], the ability of Dcytb to reduce copper is a previ-
ously unidentiﬁed function of the protein and may serve to
augment cellular copper absorption. This novel ﬁnding pro-
vides yet another link between mammalian iron and copper
metabolism [23].
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